495 related articles for article (PubMed ID: 15027457)
1. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A
Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
[No Abstract] [Full Text] [Related]
2. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
3. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
4. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
5. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
6. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
7. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
Steinhauer EH
Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
[No Abstract] [Full Text] [Related]
8. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
Silbermann JM
J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
[No Abstract] [Full Text] [Related]
9. Can the safe harbor of 35 U.S.C. section 271(e)(1) shelter pioneer drug manufacturers?
Brinckerhoff CC
Food Drug Law J; 1998; 53(4):643-59. PubMed ID: 10557582
[No Abstract] [Full Text] [Related]
10. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
11. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
12. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
13. India to consider raft of new compulsory licences.
Bagcchi S
BMJ; 2014 Jan; 348():g1094. PubMed ID: 24464388
[No Abstract] [Full Text] [Related]
14. Market-based licensing for HPV vaccines in developing countries.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
[TBL] [Abstract][Full Text] [Related]
15. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
Lexchin J
Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
[TBL] [Abstract][Full Text] [Related]
17. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
18. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
19. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
20. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
